Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.

General Committee of Teaching Hospitals and Institutes, Egypt60 enrolled

Overview

Our primary objective is to assess the effect of Liraglutide on weight loss in patients who have undergone secondary bariatric surgeries. We set out to assess if Liraglutide is a viable option to augment weight loss in said category.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Morbid Obesity

Interventions

Liraglutide Pen Injector [Saxenda]DRUG

Subcutaneous injection of GLP-1 agonist

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Undergone primary bariatric surgery * Need secondary bariatric surgery due to either weight regain (regained weight to have BMI \> 35) or medical associated diseases Exclusion Criteria: * Prior use of GLP-1 agonist * Past history of pancreatitis * Personal or family history of medullary thyroid cancer * Pregnancy or lactation * Acute coronary syndrome * Hepatic or renal dysfunction * Active malignancy

Locations (1)

Madina Women's Hospital

Alexandria, Egypt

Outcomes

Primary Outcomes

Percentage Total weight loss

Time frame: 6 months

Percentage Excess body weight loss

Time frame: 6 months

Secondary Outcomes

Comorbidities

Time frame: 6 months

Weight

Time frame: 6 months

BMI

Time frame: 6 months

HbA1C

Time frame: 6 months

Fasting Blood Glucose (FBG)

Time frame: 6 months

HOMA-IR

Time frame: 6 months

Resolution of type 2 Diabetes Mellitus

Time frame: 6 months

Blood pressure

Time frame: 6 months

Lipid profile

Time frame: 6 months

Sleep apnea

Time frame: 6 months

Central Contacts

Mohamed Ashour, PhD

CONTACT

00201002600970 dr.mhany@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.